linked in pixel

Travis King, PharmD BCPS-AQ ID

Dr. King earned his Doctor of Pharmacy degree from the University of Mississippi, School of Pharmacy. He completed his PGY1 Pharmacy Practice residency at Methodist University Hospital in Memphis, TN and went on to complete a PGY2 Infectious Diseases residency at the University of Mississippi Medical Center in Jackson, MS. Dr. King specializes in management of complex infectious diseases, antimicrobial stewardship strategies, and clinical microbiology. He is an active member of the Infectious Diseases Society of America, Society of Infectious Diseases Pharmacists, American Society of Microbiology, Clinical & Laboratory Standards Institute, and American College of Clinical Pharmacy. His practice and research interests include medical mycology, molecular detection of antimicrobial resistance, antimicrobial stewardship practice improvement, and antimicrobial toxicology.

Selected Publications

Derrick C, Bookstaver PB, Lu ZK, Bland CM, King ST, Stover KR, Rumley K, MacVane SH, Swindler J, Kincaid S, Branan T, Cluck D, Britt B, Pillinger KE, Jones BM, Fleming V, DiMondi VP, Estrada S, Crane B, Odle B, Al-Hasan MN, Justo JA. Multicenter, Observational Cohort Study Evaluating Third-Generation Cephalosporin Therapy for Bloodstream Infections Secondary to Enterobacter, Serratia, and Citrobacter Species. Antibiotics (Basel). 2020 May 14;9(5):254. doi: 10.3390/antibiotics9050254. PMID: 32423104; PMCID: PMC7277875.

Jeffres MN, Hall-Lipsy EA, King ST, Cleary JD. Systematic review of professional liability when prescribing β-lactams for patients with a known penicillin allergy. Ann Allergy Asthma Immunol. 2018 Nov;121(5):530-536. doi: 10.1016/j.anai.2018.03.010. Epub 2018 Mar 15. PMID: 29551402.

Stover KR, King ST, Barber KE. Impact of an infectious diseases advanced pharmacy practice experience on student knowledge. Curr Pharm Teach Learn. 2018 Aug;10(8):1022-1025. doi: 10.1016/j.cptl.2018.05.002. Epub 2018 Jun 11. PMID: 30314536.

Chastain DB, King ST, Stover KR. Rethinking urinary antibiotic breakpoints: analysis of urinary antibiotic concentrations to treat multidrug resistant organisms. BMC Res Notes. 2018 Jul 20;11(1):497. doi: 10.1186/s13104-018-3599-8. PMID: 30029611; PMCID: PMC6053836.

White BP, Wagner JL, Barber KE, King ST, Stover KR. Risk Factors for Failure in Complicated Intraabdominal Infections. South Med J. 2018 Feb;111(2):125-132.

Rac H, Wagner JL, King ST, Barber KE, Stover KR. Impact of an antifungal stewardship intervention on optimization of candidemia management. Ther Adv Infect Dis. 2018 Jan;5(1):3-10.

Stover KR, Kenney RM, King ST, Gross AE. Evaluation of the Use of Novel Biomarkers to Augment Antimicrobial Stewardship Program Activities. Pharmacotherapy. 2017 Dec 15.

Rac H, Stover KR, Wagner JL, King ST, Warnock HD, Barber KE. Time-Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients. Infect Dis Ther. 2017 Dec;6(4):507-513.

King ST, Barber KE, Parham JJ, Stover KR. Shifts in antimicrobial consumption and infection rates before and during a piperacillin/tazobactam shortage. J Glob Antimicrob Resist. 2017 Dec;11:111-113.

White BP, Stover KR, Barber KE, Galloway RC, Sullivan DC, King ST. Mechanisms of fosfomycin resistance in carbapenem-resistant Enterobacter sp. Int J Antimicrob Agents. 2017 Nov;50(5):690-692

Cretella D, Barber KE, King ST, Stover KR. Comparison of susceptibility patterns using commercially available susceptibility testing methods performed on prevalent Candida spp. J Med Microbiol. 2016 Dec;65(12):1445-1451.

Barber KE, Bell AM, King ST, Parham JJ, Stover KR. Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs. Braz J Infect Dis. 2016 Nov - Dec;20(6):631-634.

Barber KE, King ST, Stover KR, Pogue JM. Therapeutic options for vancomycin-resistant enterococcal bacteremia. Expert Rev Anti Infect Ther. 2015 Mar;13(3):363-77.

King ST, Walker ED, Cannon CG, Finley RW. Daptomycin-induced rhabdomyolysis and acute liver injury. Scand J Infect Dis. 2014 Jul;46(7):537-40.

Henson G, Ghonim E, Swiatlo A, King S, Moore KS, King ST, Sullivan D. Cost-benefit and effectiveness analysis of rapid testing for MRSA carriage in a hospital setting. Clin Lab Sci. 2014 Winter;27(1):13-20.

Stover KR, King ST, Cleary JD. Cardiac toxicity of the echinocandins: chance or cause and effect association? J Clin Pharm Ther. 2014 Feb;39(1):1-3.

King ST, Stover KR. Considering confounders of the galactomannan index: the role of piperacillin-tazobactam. Clin Infect Dis. 2014 Mar;58(5):751-2.

Stover KR, King ST, Robinson J. Artemether-lumefantrine: an option for malaria. Ann Pharmacother. 2012 Apr;46(4):567-77. doi: 10.1345/aph.1Q539. Epub 2012 Apr 10. PMID: 22496476.

King ST, Usery JB, Holloway K, Koeth L, Cleveland KO, Gelfand MS. Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections. J Antimicrob Chemother. 2011 Nov;66(11):2673-5. doi: 10.1093/jac/dkr343. Epub 2011 Aug 16. PMID: 21846674.

King ST, Usery JB, Cleveland KO. Adverse renal outcomes associated with antibiotic-laden spacers in two-stage joint revisions. J Infect. 2011 Dec;63(6):471-3. doi: 10.1016/j.jinf.2011.08.008. Epub 2011 Aug 16. PMID: 21867728.